New therapeutic options are now available for HR+ MBC. Dr. Virginia Kaklamani will discuss endocrine therapy resistance, liquid biopsy/blood test, mutations, and treatment sequencing of targeted therapy. You will learn about oral selective estrogen receptor degraders (SERDS), clinical trials, and more.

Subjects and Terms Included in This Episode

Novel Therapies Mentioned in the Episode

Clinical Trials Mentioned in this Episode

Meet the Guest of this Episode